Last reviewed · How we verify
NCT03573687
Effects of Protein Timing and Resistance Exercise on Fat Metabolism
NA trial testing Micellar Casein Protein in Healthy in 13 participants. Completed in 28 February 2018.
28 February 2018
Quick facts
| Lead sponsor | Florida State University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 13 |
| Start date | 20 March 2017 |
| Primary completion | 28 February 2018 |
| Estimated completion | 28 February 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Micellar Casein Protein
- Resistance Exercise Training
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Florida State University
Who can join
Adults 18 to 35, female only, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The extent to which resistance exercise training and protein timing effects localized (belly fat) and systemic (whole body) fat metabolism in resistance-trained women is unknown. Therefore, this study will assess subcutaneous abdominal adipose tissue lipolytic rate and whole body substrate utilization over the course of two trials: 1) consuming casein protein during the day, and 2) consuming casein protein at night, before bed.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Lipolysis and Fat Oxidation Are Not Altered with Presleep Compared with Daytime Casein Protein Intake in Resistance-Trained Women.
Allman BR, Morrissey MC, Kim JS, Panton LB, et al · · 2020 · cited 5× · PMID 31504693 · DOI 10.1093/jn/nxz186
Verify or expand the search:
- PubMed search for NCT03573687
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Florida State University trials
Trials by the same sponsor.
- NCT06127914 — Learning Early Infant Feeding Cues · NA · not yet recruiting
- NCT06015581 — Scaling Up Implementation Strategies to Improve the DIAGNOSE and PREVENT Pillars for Young MSM in Florida · NA · not yet recruiting
- NCT07467473 — Causal Role of Rostromedial Prefrontal Cortex for Positive Savoring in Depression · NA · enrolling by invitation
- NCT07221448 — Sodium vs Potassium Education to Improve Vascular Health · NA · recruiting
- NCT07415941 — MBM and taVNS for Low Back Pain and Depressive Symptoms · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03573687 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Florida State University
- Last refreshed: 6 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03573687.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing